Bloomage BioTechnology Corporation (00963) said it agreed to acquire an indirect 33.41% equity interest in Laboratoires Vivacy SAS at EUR59 million.
Vivacy is principally engaged in the design, development, manufacturing and sale of medical aesthetics devices including dermal fillers and cosmetics. Its hyaluronic acid injection filler is manufactured using proprietary patent technologies, which makes injection more comfortable and safer, and has been applied for registration in the PRC. Vivacy will continue to develop its own proprietary technology and to manufacture its products in France.